کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4208339 1280437 2014 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی ریوی و تنفسی
پیش نمایش صفحه اول مقاله
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
چکیده انگلیسی

BackgroundIvacaftor is used to treat patients with CF and a G551D gating mutation; the KONNECTION study assessed the efficacy and safety of ivacaftor in patients with CF and a non-G551D gating mutation.MethodsPatients with CF ≥6 -years- old with non-G551D gating mutations received ivacaftor 150 mg q12h or placebo for 8 weeks in this 2-part, double-blind crossover study (Part 1) with a 16-week open-label extension (Part 2). The primary efficacy outcome was absolute change in FEV1 through 8 and 24 weeks of ivacaftor treatment; secondary outcomes were changes in BMI, sweat chloride, and CFQ-R and safety through 8 and 24 weeks of treatment.ResultsEight weeks of ivacaftor resulted in significant improvements in percent predicted FEV1, BMI, sweat chloride, and CFQ-R scores that were maintained through 24 weeks. Ivacaftor was generally well tolerated.ConclusionsIvacaftor was efficacious in a group of patients with CF who had selected non-G551D gating mutations.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Cystic Fibrosis - Volume 13, Issue 6, December 2014, Pages 674–680
نویسندگان
, , , , , , ,